Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Combination phase I trials]

N Masuda1

  • 1Second Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Developing new cancer drug combinations is crucial for advanced treatments. This study discusses methods for selecting optimal drug combinations and doses, considering factors like synergism and toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.

ESMO open·2024
Same author

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial.

Breast cancer (Tokyo, Japan)·2018
Same author

Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Context:

  • Advanced cancer treatment increasingly relies on combination therapies.
  • Developing novel combination regimens presents a key challenge in clinical oncology.

Purpose:

  • To outline a method for selecting effective drug combinations and doses for cancer treatment.
  • To address the complexities of phase I trials for combination therapies where maximum-tolerated doses (MTDs) are known.

Summary:

  • Combination therapies offer advantages like biochemical synergism, overcoming cross-resistance, and enhanced dose-intensity by managing non-overlapping toxicities.
  • Phase I trials for drug combinations, unlike single agents, often start with known MTDs for individual drugs.
  • A systematic approach is needed to navigate the numerous possibilities in selecting drugs and their proportions for combination regimens.

Related Experiment Videos

Impact:

  • Facilitates the rational design of clinical trials for novel cancer combination therapies.
  • Aims to improve treatment efficacy and patient outcomes in advanced cancers through optimized drug combinations.